Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Cidara Secures $339M BARDA Deal for Non-Vaccine Flu Preventative, Marking Shift in U.S. Pandemic Preparedness Strategy

Cidara Secures $339M BARDA Deal for Non-Vaccine Flu Preventative, Marking Shift in U.S. Pandemic Preparedness Strategy

Cidara Therapeutics has landed a significant federal contract worth up to $339 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development and domestic manufacturing of its novel non-vaccine flu preventative, CD388. This deal comes as part of a broader shift in U.S. pandemic preparedness strategy, moving away from mRNA vaccine investments towards alternative preventative measures.

NoahAI News10/3/2025
Rocket Pharmaceuticals Withdraws Gene Therapy Application, Shifts Focus

Rocket Pharmaceuticals Withdraws Gene Therapy Application, Shifts Focus

Rocket Pharmaceuticals has voluntarily withdrawn its biologics license application (BLA) for RP-L102, a gene therapy candidate aimed at treating fanconi anemia, a rare genetic disorder characterized by bone marrow failure. This decision marks a significant shift in the company's strategic direction and pipeline priorities.

NoahAI News10/3/2025
FDA Clears Generic Abortion Pill Amid Regulatory Shifts and Biotech Breakthroughs

FDA Clears Generic Abortion Pill Amid Regulatory Shifts and Biotech Breakthroughs

The pharmaceutical landscape saw significant developments this week, with regulatory decisions, clinical trial results, and financial moves shaping the industry's trajectory. From the FDA's approval of a new generic abortion pill to promising data in epilepsy treatment and gene therapy advancements, the sector continues to evolve rapidly.

NoahAI News10/3/2025
Roche Acquires 89bio for $3.5 Billion, Driven by MASH Drug Potential

Roche Acquires 89bio for $3.5 Billion, Driven by MASH Drug Potential

In a significant move that underscores the growing importance of metabolic dysfunction-associated steatohepatitis (MASH) treatments, Roche has announced its acquisition of 89bio for $3.5 billion. The deal, which comes after months of negotiations, highlights the pharmaceutical industry's increasing focus on FGF21 class therapeutics and their potential in addressing liver diseases.

NoahAI News10/3/2025
Boston Life Sciences Job Market Shows Resilience Amid Shifting Landscape

Boston Life Sciences Job Market Shows Resilience Amid Shifting Landscape

The Boston life sciences job market continues to demonstrate resilience and growth potential, despite a recent dip in job postings. This comprehensive overview highlights the latest developments in the pharmaceutical and biotechnology sectors, showcasing the city's enduring status as a major life sciences hub.

NoahAI News10/3/2025
Autoinjectors and Combination Drug Delivery Systems: Advancing Patient Care and Clinical Trials

Autoinjectors and Combination Drug Delivery Systems: Advancing Patient Care and Clinical Trials

In a recent episode of BioSpace's podcast, industry experts discussed the evolving landscape of drug delivery systems, focusing on autoinjectors and their potential to revolutionize patient care and clinical trial processes. The conversation, featuring Oliver Eden from Jabil and Travis Webb from PII, shed light on the opportunities and challenges in this rapidly advancing field.

NoahAI News10/3/2025
Philips and Getinge Form Strategic Alliance to Streamline Anesthesia Delivery and Patient Monitoring

Philips and Getinge Form Strategic Alliance to Streamline Anesthesia Delivery and Patient Monitoring

Philips and Getinge have announced a new commercial alliance aimed at integrating their respective technologies for patient monitoring and anesthesia delivery into a unified workstation. This collaboration seeks to simplify operations in operating rooms and provide healthcare providers with a more efficient, high-quality patient care solution.

NoahAI News10/3/2025
NeueHealth Goes Private in $1.5B Deal with New Enterprise Associates

NeueHealth Goes Private in $1.5B Deal with New Enterprise Associates

NeueHealth, formerly known as Bright Health Group, has officially completed its transition to a private company following a $1.5 billion acquisition by an affiliate of New Enterprise Associates (NEA). The deal, which closed on October 2, 2025, marks a significant shift for the healthcare company and ends its tenure on the New York Stock Exchange.

NoahAI News10/3/2025
Halozyme Acquires Elektrofi for $900M, Combining Subcutaneous Drug Delivery Technologies

Halozyme Acquires Elektrofi for $900M, Combining Subcutaneous Drug Delivery Technologies

Halozyme Therapeutics has announced its acquisition of Elektrofi for up to $900 million, marking a significant consolidation in the subcutaneous drug delivery technology sector. The deal, which brings together two companies with complementary technologies and shared partnerships with major pharmaceutical firms, is set to reshape the landscape of drug administration.

NoahAI News10/3/2025
Pharmaceutical Industry Faces Wave of Layoffs Amid Strategic Shifts and Market Pressures

Pharmaceutical Industry Faces Wave of Layoffs Amid Strategic Shifts and Market Pressures

The pharmaceutical and biotech sectors are grappling with a surge of workforce reductions as companies reevaluate priorities and respond to financial headwinds. Recent weeks have seen layoff announcements from industry giants and startups alike, signaling ongoing volatility in the life sciences job market.

NoahAI News10/3/2025
Amgen's Repatha Shows Promise in Primary Prevention, Potentially Expanding Market for PCSK9 Inhibitors

Amgen's Repatha Shows Promise in Primary Prevention, Potentially Expanding Market for PCSK9 Inhibitors

Amgen has announced groundbreaking results from its Vesalius-CV trial, demonstrating that its cholesterol-lowering drug Repatha (evolocumab) met its primary endpoints in a large-scale study evaluating its use as a primary prevention therapy. This development could significantly expand the market for PCSK9 inhibitors and reshape cardiovascular disease prevention strategies.

NoahAI News10/3/2025
Medtronic Secures CE Mark for Penditure Left Atrial Appendage Implant, Expanding Stroke Prevention Options

Medtronic Secures CE Mark for Penditure Left Atrial Appendage Implant, Expanding Stroke Prevention Options

Medtronic has announced the receipt of CE Mark approval in Europe for its Penditure left atrial appendage (LAA) implant, marking a significant advancement in stroke prevention for patients with atrial fibrillation (AFib). This approval follows the device's FDA clearance in late 2023 and underscores the growing importance of LAA closure devices in cardiac care.

NoahAI News10/3/2025
«1...545556...67»